Professor Dario Alessi

OBE FRS FRSE FMedSci

Science Director (MRC)

MRC PPU, School of Life Sciences

Professor of Signal Transduction

Portrait photograph of Dario Alessi
On this page

Contact

Email

d.r.alessi@dundee.ac.uk

Phone

+44 (0)1382 388058

Biography

Dario’s research focuses on unravelling the roles of poorly characterised components which regulate protein phosphorylation or ubiquitylation pathways that are linked to human disease. Dario, obtained a BSc (1988) and PhD (1991) from the University of Birmingham, United Kingdom. 

He carried out postdoctoral at the University of Dundee from (1991 to 1997), where he became fascinated by protein kinases and how they are regulated by insulin, growth factors and other extracellular signals that control almost all aspects of cell biology. 

In 1997 Dario became a program leader in the MRC Protein Phosphorylation Unit, where he was appointed as its Director in 2012. 

Much of Dario’s current work is focused on biological research that is relevant to better understanding, treating, and preventing Parkinson’s disease. Dario also serves as the Director of the Dundee Signal Transduction Therapy Unit, a unique collaboration between scientists at the University of Dundee and pharmaceutical companies dedicated to accelerating research and development. 

Dario is passionate about mentorship, open science, sharing, working with industry and clinicians, as well as fostering a collaborative culture. He is motivated to bring talented scientists into the Parkinson’s research field and improve awareness of issues relating to equality, diversity, inclusion, gender, and mental health. 

Dario was elected as Fellow of the Royal Society of Edinburgh (2002), Fellow of the Royal Society (2008), and Fellow of the UK Academy of Medical Sciences (2012). He received the EMBO Gold Medal (2005), the Francis Crick Prize of the Royal Society (2006), the MJFF Langston Award (2017), the Louis Jeantet-Collen Prize for Translational Medicine (2023), an Order of the British Empire (2023) and the MJFF Robert A. Pritzker Prize for Leadership in Parkinson’s Research (2023). 

Dario has published approaching 300 papers (~100 000 cumulative citations) and has a h-index of 153. To peruse Dario’s publications see Google Scholar

Research

LRRK2 Pathway and Parkinson’s Disease

Motivated by the lack of a molecular understanding and a treatment that slows down the progression of Parkinson’s disease, our research focuses on the leucine-rich repeat kinase-2 (LRRK2) pathway, as mutations that increase the kinase activity of LRRK2, represent one of the most common inherited causes of Parkinson’s disease. The goal of our work is to undertake high quality rigorous research  to develop a robust framework of knowledge of how the LRRK2 signalling pathways is regulated, to develop improved methods to better diagnose and treat Parkinson’s disease.

A summary of our current understanding of the LRRK2 signalling pathway based on our research and that of others is presented in Figure 1.

A graphic showing LRRK2 signalling pathway and Parkinson’s Disease

Figure 1: LRRK2 signalling pathway

LRRK2 is a large multidomain protein consisting of two catalytic domains namely an atypical GTPase and a protein kinase domain. Pathogenic mutations that activate LRRK2 are found in the kinase and GTPase as well as other domains and are thought to destabilise the inactive conformation of LRRK2 1. We have found that LRRK2 phosphorylates a subgroup of Rab GTPase proteins (Rab1, Rab3, Rab8, Rab10, Rab12, Rab29, Rab35, and Rab43) 2,3, that coordinate membrane homeostasis and endocytic and exocytic pathways. LRRK2 phosphorylates Rab substrates at a conserved Ser or Thr site lying at the centre of the effector-binding switch-II motif (Thr72 for Rab8A, Thr73 for Rab10, and Ser106 for human Rab12) 2,3. We also discovered that this reaction is counteracted by the PPM1H, a highly selective protein phosphatase that efficiently dephosphorylates Rab proteins 4,5.

We have identified 4 scaffolding proteins, namely RILPL1, RILPL2, JIP3 and JIP4, that specifically interact with LRRK2 phosphorylated Rab8A and Rab10 with higher affinity than dephosphorylated Rab proteins 2,6. The interaction of RILPL1 with phosphorylated Rab proteins interferes with ciliogenesis 2 and in cholinergic neurons in the striatum leads to disruption of a Sonic hedgehog neuro-protective circuit that supports dopaminergic neurons, providing a pathway by which LRRK2 may be linked to Parkinson’s disease pathology 7.

Rab proteins are not only substrates but also play a key role in controlling LRRK2 kinase activity by binding to the N-terminal ARM domain and recruiting LRRK2 to membranes where it becomes activated 8,9. Recent work has pinpointed 3 Rab binding sites within the LRRK2 ARM domain (Figure 2). Site-1 binds to dephosphorylated Rab29, Rab32 as well as Rab8 and possibly Rab10 10,11. Site-2 interacts specifically to LRRK2-phosphorylated Rab8 and Rab10 in a feed-forward pathway that drives membrane recruitment and activation of LRRK2 10. Site-3 interacts with Rab12 and ablation of this site or knock-out of Rab12 has the largest effect in regulating the basal activity of LRRK2 12.

Graphic showing location of three Rab binding sites on the LRRK2 ARM domain

Figure 2: Location of three Rab binding sites on the LRRK2 ARM domain that regulate recruitment of LRRK2 to membranes

The D620N mutation in the VPS35 component of the retromer complex transports select endosomal cargo proteins between endosomal compartments and the Golgi and has been linked to Parkinson’s disease and stimulates the LRRK2 pathway via an unknown mechanism 13. VPS35[D620N] knock-in cells and tissues display markedly enhanced Rab phosphorylation to a higher level than observed with LRRK2 pathogenic mutations 13,14 and this mutation has been proposed to lead to lysosomal dysfunction. Our on-going work suggests that the D620N VPS35 mutation disrupts selective endosomal cargo trafficking triggering lysosomal dysfunction, thereby activating LRRK2 (Figure 1).

Key questions for on-going work

We wish to define the mechanism by which LRRK2 is recruited to the stressed/damaged lysosome and the role that LRRK2 plays once recruited to the lysosome. We have identified a novel pathway involving LRRK2 controlling the binding of the phospho Rab protein to RILPL1 and the lysosomal protein TMEM55B, that wish to study further. We are also keen to uncover other proteins that interact with LRRK2 phosphorylated Rab proteins including Rab12 and characterise these further. We are also keen to undertake unbiased screens to identify new regulators of the LRRK2 signalling pathway and use this knowledge to develop improved biomarkers and therapeutic strategies to better diagnose and treat LRRK2 driven Parkinson’s disease.

It is exciting times in this research field as late phase clinical trials of LRRK2 inhibitors are underway and targeting this pathway is one of the most promising therapeutic strategies to slow progression of Parkinson’s disease.

Collaboration, open science, culture and mentorship

Alessi lab has a strong track record of fostering collaborations and conducting open science.  This includes his Parkinson’s disease research with the Michael J Fox Foundation for Parkinson’s Research and Aligning Science Across Parkinson’s as well as the UK Dementia Research Initiative. He contributes to general research on protein phosphorylation and ubiquitylation by directing the MRC Protein Phosphorylation and Ubiquitylation Unit and supports pharmaceutical companies with their research in this field through the Division of Signal Transduction Unit and other collaborations.

To help the global research community Alessi lab promotes sustainable science practices by freely sharing all reagents and services via the MRC Pure Agents website  and other reagents websites such as LRRK2.bio. All of Alessi’s lab protocols are now deposited on Protocols.io and papers submitted to preprint servers such as Biorxiv at or before the time of submission. He is also participating on a new UK "National Asset" program to enable all MRC Unit- and Institute-generated tools, data, and technologies to be made available from a web database.

The Alessi lab aims to undertake high quality research, promote a strong sharing culture between researchers and help disseminate tools/data/technologies to better enable scientists to replicate data and support worldwide research.

We are strong supporters of working hard to continuously improve equality and diversity in a multidisciplinary environment, paying attention to cultivating culture and development best practices. Dario has trained over 30 graduate students and 40 postdoctoral researchers, the majority now in leadership positions in academia and industry.

 

Google Scholar image with words relating to Dario Alessi's work.

Louis-Jeantet Foundation video showcasing Alessi lab and its research

References

1          Kalogeropulou, A. F. et al. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding. Biochem J 479, 1759-1783 (2022). https://doi.org/10.1042/BCJ20220161

2          Steger, M. et al. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife 6, e31012 (2017). https://doi.org/10.7554/eLife.31012

3          Steger, M. et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, e12813 (2016). https://doi.org/10.7554/eLife.12813

4          Berndsen, K. et al. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. eLife 8, e50416 (2019). https://doi.org/10.7554/eLife.50416

5          Waschbüsch, D., Berndsen, K., Knebel, A., Alessi, D. R. & Khan, A. R. Structural basis for the specificity of PPM1H phosphatase for Rab GTPases. bioRxiv, 2021.2002.2017.431620 (2021). https://doi.org/10.1101/2021.02.17.431620

6          Waschbüsch, D. et al. Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure 28, 406-417.e406 (2020). https://doi.org/10.1016/j.str.2020.01.005

7          Dhekne, H. S. et al. A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. Elife 7, e40202 (2018). https://doi.org/10.7554/eLife.40202

8          Purlyte, E. et al. Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO J 37, 1-18 (2018). https://doi.org/10.15252/embj.201798099

9          Liu, Z. et al. LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum Mol Genet 27, 385-395 (2018). https://doi.org/10.1093/hmg/ddx410

10        Vides, E. G. et al. A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation. Elife 11 (2022). https://doi.org/10.7554/eLife.79771

11        Zhu, H., Tonelli, F., Alessi, D. R. & Sun, J. Structural basis of human LRRK2 membrane recruitment and activation. bioRxiv, 2022.2004.2026.489605 (2022). https://doi.org/10.1101/2022.04.26.489605

12        Dhekne, H. S. et al. Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase. bioRxiv, 2023.2002.2017.529028 (2023). https://doi.org/10.1101/2023.02.17.529028

13        Mir, R. et al. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. The Biochemical journal 475, 1861-1883 (2018). https://doi.org/10.1042/BCJ20180248

14        Nirujogi, R. S. et al. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites. Biochem J 478, 299-326 (2021). https://doi.org/10.1042/BCJ20200930

 

Selected Recent Publications

1          Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., Baptista, M. A., Fiske, B. K., Fell, M. J., Morrow, J. A., Reith, A. D., AlessiDR. and Mann, M. (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 5,e12813

https://elifesciences.org/articles/12813

2          Steger, M., Diez, F., Dhekne, H. S., Lis, P., Nirujogi, R. S., Karayel, O., Tonelli, F., Martinez, T. N., Lorentzen, E., Pfeffer, S. R., AlessiDR. and Mann, M. (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife. 6,e31012

https://elifesciences.org/articles/31012

3          Ito, G., Katsemonova, K., Tonelli, F., Lis, P., Baptista, M. A., Shpiro, N., Duddy, G., Wilson, S., Ho, P. W., Ho, S. L., Reith, A. D. and AlessiDR. (2016) Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors. Biochem J. 473, 2671-2685

https://portlandpress.com/biochemj/article-lookup/doi/10.1042/BCJ20160557

4          Waschbüsch, D., Purlyte, E., Pal, P., McGrath, E., AlessiDR. and Khan, A. R. (2019) Structural basis for Rab8a GTPase recruitment of RILPL2 via LRRK2 phosphorylation of switch 2. bioRxiv, 739813

https://www.biorxiv.org/content/10.1101/739813v1

5          Dhekne, H. S., Yanatori, I., Gomez, R. C., Tonelli, F., Diez, F., Schule, B., Steger, M., AlessiDR. and Pfeffer, S. R. (2018) A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. Elife. 7, e40202

https://elifesciences.org/articles/40202

6          Purlyte, E., Dhekne, H. S., Sarhan, A. R., Gomez, R., Lis, P., Wightman, M., Martinez, T. N., Tonelli, F., Pfeffer, S. R. and AlessiDR. (2018) Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO J. 37, 1-18

https://www.embopress.org/doi/full/10.15252/embj.201798099

7          Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., Chou, M.-Y., Howden, A. J. M., König, T., Hotzy, C., Milenkovic, I., Brücke, T., Zimprich, A., Sammler, E. and AlessiDR. (2018) The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem J. 475, 1861-1883

https://portlandpress.com/biochemj/article-lookup/doi/10.1042/BCJ20180248

8          Lis, P., Burel, S., Steger, M., Mann, M., Brown, F., Diez, F., Tonelli, F., Holton, J. L., Ho, P. W., Ho, S. L., Chou, M. Y., Polinski, N. K., Martinez, T. N., Davies, P. and AlessiDR. (2018) Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase. Biochem J. 475, 1-22

https://portlandpress.com/biochemj/article-lookup/doi/10.1042/BCJ20170802

9          Fan, Y., Howden, A. J. M., Sarhan, A. R., Lis, P., Ito, G., Martinez, T. N., Brockmann, K., Gasser, T., AlessiDR. and Sammler, E. M. (2018) Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J. 475, 23-44

https://portlandpress.com/biochemj/article-lookup/doi/10.1042/BCJ20170803

10        Berndsen, K., Lis, P., Yeshaw, W. M., Wawro, P. S., Nirujogi, R. S., Wightman, M., Macartney, T., Dorward, M., Knebel, A., Tonelli, F., Pfeffer, S. R. and AlessiDR. (2019) PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife. 8, e50416

https://elifesciences.org/articles/50416

 

For an up to date list of Dario’s publications, click here https://scholar.google.co.uk/citations?hl=en&user=9gPyVfsAAAAJ&view_op=list_works&sortby=pubdate

View full research profile and publications

Media availability

I am available for media commentary on my research.

Professor Alessi is a biochemical engineer whose research focuses on opening up our understanding of human health and disease. Much of his current work focuses on understanding a gene involved in Parkinson’s called LRRK2 and aims to exploit findings on this to develop improved ways to better diagnose and treat the disease.

Contact Corporate Communications for media enquiries.

Areas of expertise

  • Alzheimer’s disease
  • Parkinson’s disease

Awards

Award Year
Order of the British Empire (OBE) / Officer of the Order of the British Empire (OBE) 2023
International Science Prizes awarded since 1990 / The Michael J. Fox Foundation Robert A. Pritzker Prize for Leadership in Parkinson’s Research2023 2023
International Science Prizes awarded since 1990 / Jeantet-Collen Prize for Translational Medicine 2023
Fellow of the Academy of Medical Sciences 2012
Fellow of the Royal Society 2008
Member of the European Molecular Biology Organisation 2005
International Science Prizes awarded since 1990 / EMBO Gold Medal 2005
International Science Prizes awarded since 1990 / The Federation of Biochemical Society's Anniversary Prize for Outstanding Achievement 2003
International Science Prizes awarded since 1990 / The G.B. Morgagni Young Investigator Prize, Italy 2002
International Science Prizes awarded since 1990 / The Pfizer Academic Award for Europe 2002
National Sciences Prizes awarded since 1990 / Makdougall Brisbane Prize of The Royal Society of Edinburgh 2002
Fellow of the Royal Society of Edinburgh 2002
National Sciences Prizes awarded since 1990 / The Philip Leverhulme Prize 2002
International Science Prizes awarded since 1990 / The Eppendorf European Young Investigator of the Year, Germany 2000
National Sciences Prizes awarded since 1990 / The Colworth Medal of the British Biochemical Society 2000

Stories